Treatment options for hepatocellular carcinoma using immunotherapy: present and future

Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms. The tumor microenvironment plays a pivotal role in fostering immune suppression and maintaining self-tolerance, which are crucial in developing and refining immunotherapy approaches.

In our comprehensive review, we initially delve into the characteristics of the tumor microenvironment in HCC, elucidating the predominant immunosuppressive mechanisms at play and the biomarkers pivotal for tracking the disease progression and therapeutic response. Key biomarkers such as α-fetoprotein (AFP), used for diagnosis and monitoring, and emerging molecular markers are extensively discussed.

Central to our discussion is the transformative role of antibody-based therapies, particularly immune checkpoint inhibitors (ICIs). These therapies, which include monoclonal antibodies targeting programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and programmed death-ligand 1 (PD-L1), have revolutionized the approach to HCC treatment. We delve into the specifics of how these therapies reinvigorate the immune system’s ability to recognize and attack tumor cells, discussing their application both as monotherapies and in combination with other targeted therapies. This segment underscores the significance of ICIs in managing advanced HCC, providing new avenues for first-line and subsequent treatments.

Additionally, the review explores various cellular immunotherapies such as T cell receptor (TCR) T cell therapy and chimeric antigen receptor (CAR) T cell therapy. The adaptability of these therapies to individual patient profiles illustrates the shift towards personalized medicine in oncology, aiming to optimize treatment efficacy based on unique tumor characteristics and patient immune profiles.

The potential of HCC vaccines, adjuvant immunotherapy, and oncolytic virotherapy is also thoroughly reviewed. Each of these therapeutic strategies exemplifies cutting-edge advances aiming to prime the immune system more effectively against HCC. We discuss the development stages of various vaccine types, their mechanisms of action, and the potential they hold in preventing recurrence and prolonging patient survival.

In conclusion, our detailed review highlights the dynamic and rapidly evolving landscape of HCC treatment. It reflects on the significant strides made in harnessing the immune system against HCC through innovative immunotherapies and sets the stage for future research that could unlock even more effective treatment modalities. The continuous refinement of immunotherapeutic approaches promises to enhance outcomes for patients with HCC, transforming the prognosis of this challenging cancer.

Full text

https://www.xiahepublishing.com/2310-8819/JCTH-2023-00462

The study was recently published in the Journal of Clinical and Translational Hepatology.

The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study’s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.

Follow us on X: @xiahepublishing

Follow us on LinkedIn: Xia & He Publishing Inc.